Home › XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)
 

Keywords :   


XELJANZ (Tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA)

2013-03-25 08:00:00| drugdiscoveryonline News Articles

Pfizer Inc. announced recently that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved XELJANZ (tofacitinib citrate) for the treatment of adults with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies

Tags: with japan treatment approved

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Phibro Animal Health completes acquisition of Zoetis medicated feed additive portfolio
05.11November/December 2024 Digital Edition of National Hog Farmer now available
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »